CD274 and small cell lung carcinoma: Shuo Kang et al. [27] conducted a network meta-analysis (NMA) to compare the efficacy and evaluate the cost-effectiveness of PD-1 plus chemotherapy and PD-L1 plus chemotherapy as first-line treatments for ES-SCLC from the perspective of the Chinese health care system.